Characteristics of survivor and non-survivors with hypertension hospitalized with COVID-19
| Characteristics | Survivor (n=204) | Non-survivor (n=46) | P value |
| Age (years) | 37±4 | 40±6 | 0.07 |
| Gender (male/female) | 117/87 | 19/27 | 0.65 |
| Smoking | 18 (8.7) | 5 (10.4) | 0.25 |
| Antihypertensive medications, n (%) | |||
| ACEI/ARB | 137 (67.1) | 26 (56.7) | 0.076 |
| Calcium channel blockers | 45 (22.2) | 17 (36.0) | 0.23 |
| Beta blockers | 68 (33.5) | 14 (30.9) | 0.87 |
| Other medications, n (%) | |||
| Anticoagulant therapy | 13 (6.3) | 4 (7.9) | 0.43 |
| Aspirin | 63 (31.1) | 17 (37.3) | 0.056 |
| Statins | 34 (16.6) | 11 (23.4) | 0.092 |
| Furosemide | 10 (5.0) | 3 (7.2) | 0.08 |
| Laboratory data | |||
| White cell count (×109/L) | 5.10±2.12 | 8.93±4.31 | 0.004 |
| Hemoglobin (mg/dL) | 11.9±1.3 | 12.1±1.7 | 0.53 |
| Hematocrit | 41.2±4.0 | 40.9±3.9 | 0.37 |
| Glucose (mg/dL) | 98±34 | 119±49 | 0.045 |
| Creatinine (mg/dL) | 1.11±0.19 | 1.60±0.78 | <0.005 |
| Uric acid (mg/dL) | 6.0±1.4 | 4.7±1.2 | 0.68 |
| AST (IU/L) | 22±9 | 24±8.8 | 0.79 |
| ALT (IU/L) | 30±12 | 32±11 | 0.94 |
| Lactate dehydrogenase (U/L) | 406±132 | 469±187 | 0.09 |
| C reactive protein (mg/dL) | 27.9±38.7 | 119.1±75.8 | 0.02 |
| D-dimer (mg/L) | 1.39±0.3 | 4.18±29 | 0.02 |
| Creatine kinase (mg/dL) | 93±87 | 118±68 | 0.54 |
| CK-MB (mg/dL) | 0.8±0.5 | 0.8±0.5 | 0.82 |
| Troponin | 12.1±9.0 | 13.1±8.2 | 0.66 |
| ProBNP | 49±34 | 57±31 | 0.12 |
| Hospital stay, days | 7±4 | 12±8 | 0.086 |
ACEI, ACE inhibitor; ARB, angiotensin receptor blocker; AST, aspartate aminotransferase.